Literature DB >> 18642766

[Frequency and transcript variant analysis of gene fusions between TMPRSS2 and ETS transcription factor genes in prostate cancer].

Mei-Jie Dai1, Li-Li Chen, Yan-Bo Zheng, Wei Chen, Zhi-Hua Tao, Zhi-Liang Weng, Xiu-Ling Wu, Cheng-Di Li, Zhan-Guo Chen, Xiao-Dong Chen, Shao-Bo Shi.   

Abstract

OBJECTIVE: To investigate the frequencies and types of fusions between the transmembrane protease serine 2 (TMPRSS2), ETS-related gene (ERG), ETS variant-1 (ETV1), and ETS variant-4 (ETV4) genes in prostate cancer (PCa) and significance thereof.
METHODS: Biopsy samples of prostate were obtained under transrectal ultrasound (TRUS) from 32 PCa patients, aged (74 +/- 8) and 34 patients with benign prostate hyperplasia (BPH). Nested RT-PCR and direct DNA sequencing were used to detect the fusion genes of TMPRSS2/ERG, TMPRSS2/ETV1, and TMPRSS2/ETV4. The association between the fusion-positive tumor rate and Gleason grading was analyzed.
RESULTS: Of the 32 PCa patients, TMPRSS2/ERG fusion was detected in 17 cases (53.1%), including 5 variant fusion transcripts one of which was newly discovered with the GenBank accession number of EU090248. TMPRSS2/ETV1 fusion was detected in only 2 cases (6.3%), including one newly discovered variant fusion transcripts with the GenBank accession number of EU090249. TMPRSS2/ETV4 fusion was not detected. The positive rates of TMPRSS2/ERG and TMPRSS2/ETV1 fusions showed no statistical association with the Gleason grade (P = 0.169). No fusion between the TMPRSS2 and ETS transcription factor genes was detected in the 34 BPH samples.
CONCLUSION: TMPRSS2/ERG and TMPRS22/ETV1 fusion genes with different subtypes exist in the tissues of PCa. TMPRSS2/ERG and TMPRSS2/ETV1 fusion genes may be used as diagnostic tools for PCa.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18642766

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  6 in total

1.  TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.

Authors:  Hui Jiang; Xueying Mao; Xiaoyi Huang; Jing Zhao; Lumei Wang; Jingjing Xu; Hongwei Zhang; Yongjie Lu; Yongwei Yu
Journal:  Tumour Biol       Date:  2016-06-20

Review 2.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

Review 3.  Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and meta-analysis.

Authors:  Yanhong Yao; Haitao Wang; BaoGuo Li; Yong Tang
Journal:  Tumour Biol       Date:  2013-10-20

4.  Expression of ERG Protein and TMRPSS2-ERG Fusion in Prostatic Carcinoma in Egyptian Patients.

Authors:  Ahmed Abdel-Hady; Ali El-Hindawi; Olfat Hammam; Heba Khalil; Sara Diab; Soulafa Abd El-Aziz; Mohamed Badawy; Ahmed Ismail; Noha Helmy; Nora Kamel; Shady Anis; Amr El Kholy; Khalid Al Osili; Afaf Abdel-Hady; Hani Nour; Maha Akl
Journal:  Open Access Maced J Med Sci       Date:  2017-03-20

5.  Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review.

Authors:  De-Pei Kong; Rui Chen; Chun-Lei Zhang; Wei Zhang; Guang-An Xiao; Fu-Bo Wang; Na Ta; Xu Gao; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2020 Mar-Apr       Impact factor: 3.285

6.  Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.

Authors:  Ritu Bhalla; Lakshmi P Kunju; Scott A Tomlins; Kelly Christopherson; Connie Cortez; Shannon Carskadon; Javed Siddiqui; Kyung Park; Juan Miguel Mosquera; Gary A Pestano; Mark A Rubin; Arul M Chinnaiyan; Nallasivam Palanisamy
Journal:  Mod Pathol       Date:  2013-01-25       Impact factor: 7.842

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.